Rubius Therapeutics Inc (NASDAQ:RUBY) Director Robert Langer sold 7,500 shares of the stock in a transaction on Monday, April 15th. The stock was sold at an average price of $17.57, for a total transaction of $131,775.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Shares of NASDAQ RUBY opened at $17.04 on Friday. The firm has a market cap of $1.47 billion and a P/E ratio of -7.51. Rubius Therapeutics Inc has a 12-month low of $12.70 and a 12-month high of $33.01. The company has a debt-to-equity ratio of 0.17, a quick ratio of 20.72 and a current ratio of 20.72.

Rubius Therapeutics (NASDAQ:RUBY) last issued its earnings results on Thursday, March 28th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.42) by $0.07. Equities research analysts predict that Rubius Therapeutics Inc will post -1.71 earnings per share for the current fiscal year.

Several equities research analysts have recently weighed in on RUBY shares. Zacks Investment Research upgraded shares of Rubius Therapeutics from a “hold” rating to a “buy” rating and set a $16.00 price objective for the company in a research report on Wednesday, January 16th. ValuEngine cut shares of Rubius Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, December 21st. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Rubius Therapeutics has an average rating of “Buy” and an average target price of $30.00.

A number of hedge funds and other institutional investors have recently modified their holdings of RUBY. Rhumbline Advisers bought a new position in Rubius Therapeutics during the third quarter worth $207,000. Bank of New York Mellon Corp bought a new position in Rubius Therapeutics during the third quarter worth $707,000. BlackRock Inc. bought a new position in Rubius Therapeutics during the third quarter worth $38,155,000. JPMorgan Chase & Co. bought a new position in Rubius Therapeutics during the third quarter worth $7,512,000. Finally, MetLife Investment Advisors LLC bought a new position in Rubius Therapeutics during the third quarter worth $405,000. 87.07% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: This story was first published by Daily Political and is owned by of Daily Political. If you are reading this story on another publication, it was illegally copied and reposted in violation of international trademark and copyright law. The legal version of this story can be viewed at https://www.dailypolitical.com/2019/04/19/rubius-therapeutics-inc-ruby-director-robert-langer-sells-7500-shares.html.

Rubius Therapeutics Company Profile

Rubius Therapeutics, Inc focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases through its rubius erythrocyte design cellular therapy platform. The company is developing various RCTs, such as RTX-134 for treatment of classic and moderate phenylketonuria; RTX-Uricase/URAT1 for treatment of chronic refractory gout; RTX-CBS for treatment of homocystinuria; RTX-OxOx for the treatment of second-line hyperoxaluria; and RTX-ALAD for the treatment of acute intermittent porphyria.

Read More: Investing in Growth Stocks

Receive News & Ratings for Rubius Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rubius Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.